An intact gut commensal microbiota, which is a population of microorganisms living in the intestine, is required for optimal response to cancer therapy, according to a mouse study by scientists at the National Cancer Institute (NCI)
Introduction of the UroNav was the result of nearly a decade’s research and development, principally conducted at NCI. Resembling a stylized computer workstation on wheels, the system electronically fuses together pictures from magnetic resonance imaging and ultrasound to create a detailed, three-dimensional view of the prostate, which physicians can then use to guide precision biopsies.
To address concerns of colorectal cancer recurring after initial treatment, NCI, in collaboration with SWOG, one of NCI’s cooperative groups, recently announced a phase III trial that looks at whether someone who has been treated for colon cancer in the past can lower his or her risk of having a second primary colorectal cancer or an adenoma by regularly taking one or both of the study drugs, eflornithine and sulindac.
NCI funded a clinical trial that will have an impact on the treatment of late-stage cervical cancer, and also supported a screening trial in India using a network of community outreach workers offering low tech-screening by direct visualization of the cervix coated with dilute acetic acid (vinegar), a process known as VIA. Image depicts cervical cancer microvessel density which increases lethality of the cancer.
More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population. Depicted are members of NCI’s Pediatric Oncology Branch. From left: Drs. Crystal Mackall, Daniel Lee, and Alan Wayne
The Annual Report to the Nation on the Status of Cancer, 1975–2009, shows that overall cancer death rates continued to decline in the U.S. among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites.
- NIH mouse study finds gut microorganisms may determine cancer treatment outcomeNovember 21, 2013
- Worldwide trends show oropharyngeal cancer rates increasingNovember 20, 2013
- Study finds low-intensity therapy for Burkitt lymphoma highly effectiveNovember 13, 2013
- Fewer doses of HPV vaccine result in immune response similar to three-dose regimenNovember 4, 2013
Obtaining an NCI designation for a cancer center is usually a years-long process of building — facilities, faculty, and most importantly, a research portfolio — culminated by a rigorous review process. Selection provides recognition of research excellence
- 3-D mammography increases cancer detection and reduces call-back ratesDecember 4, 2013
- New drug cuts risk of deadly transplant side effect in halfDecember 3, 2013
- Antioxidant blocking in cancer cells reduces tumor growth in miceDecember 3, 2013
- Predicting outcome for high-dose IL-2 therapy in cancer patientsDecember 3, 2013